Published on : Apr 02, 2020
The global uterine fibroids treatment market is expected to witness major growth as cancer cases continue to rise, creating more awareness, and driving more diagnostics to register more growth. The uterine fibroids are non-cancerous lumps, however the lump can remain difficult to detect without active measure by patients. The lump similar in looks to forms of cancerous tumours, results in more detection today than ever before, thanks to rising incidences of cancer.
ResearchMoz has released a report titled “Global uterine fibroids treatment Market market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2019 - 2030.” The report offers the growth scenarios present globally as well as revenues of the overall market. The Global uterine fibroids treatment market report thoroughly discusses robust growth prospects and prominent strategies implicated by several key players operating in the global market, which are likely to benefit the market growth and grab leading position in terms of revenue in the market. The report is available on the website ResearchMoz.us as well.
Rising Awareness Key to Growth for the Uterine Fibroids Treatment Market
Uterine fibroids can result in abnormal swelling, sometimes reaching 40% to normal body size. The swelling often causes pain, bleeding, anaemia, and infertility even. The growth of uterine fibroids has resulted in significant loss of interest in life for many, and is a major reason for hysterectomy. Various treatment options like progestins, medicinal management, and oral contraceptives are available for treatment in the market. Moreover, ablation, myomectromy, and GnRH agonists are also some other available option for patients.
However, despite a wide range of available treatments, the lack of awareness about the condition, and several unaware patients, the disease often goes unnoticed to most. The disease is estimated to affect over 20 million women in North America. On the other hand, 24 million in Europe suffer from the condition, while the global detection rates remain abysmal with 7 million reported cases globally.
Oral Contraceptives to Remain Most Dominant Treatment Segment
Non-harmonal care including non-steroidal anti-inflammatory agents or NSAIDS, and hormonal treatments like contraceptives, and GnRH are two major treatment options. Additionally, surgical options will also be covered in the report. Among these, the hormonal treatment options promise growth as ease of use, cost-effective nature, and delicate nature of most women suffering from uterine fibroids treatment will drive growth for the segment. The effective treatment for the oral contraceptives and other options also remain most promising for patients. This is expected to drive new opportunities for players in the uterine fibroids treatment market.
Request a Sample PDF copy with detailed Insights: https://www.researchmoz.us/enquiry.php?type=S&repid=2439143
The growing awareness of the condition and innovation in treatments will likely open up new opportunities for players in the global uterine fibroids treatment market during the forecast period. The ease of use of medication will also draw new patients, who are wary of surgical procedures.
Some of Major players in uterine fibroid market are Boston Scientific Corporation, Cooper Surgical, C.R. Bard, F. Hoffmann-La Roche Ltd, GE Healthcare, Karl Storz Endoscopy, Richard Wolf Medical Instruments and Siemens Medical Solutions, AbbVie Inc., AstraZeneca, Bayer AG, Eli Lilly and Company, GlaxoSmithKline Pharmaceuticals Limited, Pfizer Inc., Johnson & Johnson and Novartis AG.